Clinical Trials
49 trialsNCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03500874 2024-01-22
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
Sun Yat-sen University
Phase 3 Terminated
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT00601198 2023-08-01
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Phase 2 Terminated
NCT00002525 2023-06-28
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
Eastern Cooperative Oncology Group
Phase 3 Terminated
NCT03678428 2023-02-16
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
Sun Yat-sen University
Phase 3 Terminated
NCT02384850 2022-04-08
SENTINEL
GSO Global Clinical Research BV
Phase 1 Terminated
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT00005944 2021-02-17
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
UNICANCER
Phase 2 Terminated
NCT03368859 2021-02-09
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
Phase 2 Terminated
NCT00023868 2020-12-02
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
American College of Radiology Imaging Network
Phase 3 Terminated
NCT03300609 2020-06-11
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
University of Southern California
Phase 3 Terminated
NCT00602329 2020-04-28
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02141295 2020-03-25
McCAVE
Hoffmann-La Roche
Phase 2 Terminated
NCT00541112 2020-02-11
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
UNICANCER
Phase 2 Terminated
NCT01479465 2019-04-17
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Phase 2 Terminated
NCT02568046 2019-03-26
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Symphogen A/S
Phase 1/2 Terminated
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00077233 2018-05-16
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01765582 2017-09-18
STEAM
Hoffmann-La Roche
Phase 2 Terminated
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT00040391 2016-12-01
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Celgene Corporation
Phase 2 Terminated
NCT01858662 2016-04-15
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT00755118 2015-10-07
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
University Hospital of Crete
Phase 2 Terminated
NCT01375816 2015-06-04
PEPCOL
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00720512 2015-03-11
BEBYP
Gruppo Oncologico del Nord-Ovest
Phase 3 Terminated
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00006037 2014-05-22
Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
University of Southern California
Phase 2 Terminated
NCT00323011 2014-05-21
FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
University of Southern California
Phase 2 Terminated
NCT00006015 2013-05-03
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00889343 2013-03-04
FOSCO
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00043004 2012-09-24
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00110721 2012-03-06
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Terminated
NCT00065117 2011-01-26
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
AstraZeneca
Phase 2 Terminated
NCT00106054 2010-08-27
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Pfizer
Phase 2 Terminated
NCT00037180 2008-09-29
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Pfizer
Phase 2 Terminated
NCT00385021 2007-11-02
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
Southwestern Regional Medical Center
Phase 2 Terminated
NCT00209703 2006-04-21
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 2 Terminated
NCT00044785 2005-06-24
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Wellstat Therapeutics
Phase 1 Terminated